AR116394A2 - Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato - Google Patents

Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato

Info

Publication number
AR116394A2
AR116394A2 ARP190102595A ARP190102595A AR116394A2 AR 116394 A2 AR116394 A2 AR 116394A2 AR P190102595 A ARP190102595 A AR P190102595A AR P190102595 A ARP190102595 A AR P190102595A AR 116394 A2 AR116394 A2 AR 116394A2
Authority
AR
Argentina
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
phenyl
Prior art date
Application number
ARP190102595A
Other languages
English (en)
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of AR116394A2 publication Critical patent/AR116394A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Reivindicación 1: Un compuesto caracterizado porque es el mesilato de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]acetamida monohidrato cristalino.
ARP190102595A 2011-09-26 2019-09-13 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato AR116394A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11007823A EP2573086A1 (en) 2011-09-26 2011-09-26 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Publications (1)

Publication Number Publication Date
AR116394A2 true AR116394A2 (es) 2021-05-05

Family

ID=46889067

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP120103551A AR088043A1 (es) 2011-09-26 2012-09-26 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
ARP190102595A AR116394A2 (es) 2011-09-26 2019-09-13 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
ARP200102938A AR120291A2 (es) 2011-09-26 2020-10-23 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-triazol-2-il]n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120103551A AR088043A1 (es) 2011-09-26 2012-09-26 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200102938A AR120291A2 (es) 2011-09-26 2020-10-23 Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-triazol-2-il]n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato

Country Status (29)

Country Link
US (1) US9340535B2 (es)
EP (3) EP2573086A1 (es)
JP (2) JP6161614B2 (es)
KR (4) KR20170055565A (es)
CN (2) CN105541829A (es)
AR (3) AR088043A1 (es)
AU (2) AU2012314536B2 (es)
CA (1) CA2791142C (es)
CL (1) CL2014000149A1 (es)
DK (2) DK2598501T3 (es)
ES (2) ES2462492T3 (es)
HK (1) HK1220978A1 (es)
HR (1) HRP20140351T1 (es)
IL (2) IL230152A (es)
IN (1) IN2014DN01993A (es)
JO (2) JO3037B1 (es)
MX (2) MX338736B (es)
MY (2) MY190878A (es)
NZ (1) NZ718867A (es)
PE (1) PE20141148A1 (es)
PH (1) PH12015502801A1 (es)
PL (2) PL2598501T3 (es)
PT (1) PT2598501E (es)
RU (2) RU2620604C2 (es)
SG (1) SG10201407430TA (es)
TW (2) TWI567070B (es)
UA (2) UA119574C2 (es)
WO (1) WO2013045479A1 (es)
ZA (2) ZA201401773B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
AR108175A1 (es) * 2016-04-06 2018-07-25 Innovative Molecules Gmbh Compuestos antivíricos de tiazol acetamida
TW201825095A (zh) * 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
US11266636B2 (en) * 2016-11-28 2022-03-08 Aicuris Gmbh & Co. Kg Maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
US11021474B2 (en) * 2016-11-28 2021-06-01 Aicuris Anti-Infective Cures Gmbh N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
KR102335327B1 (ko) 2017-04-28 2021-12-03 현대자동차 주식회사 수냉식 이지알 쿨러
DK3644958T3 (da) * 2017-06-28 2021-10-25 Aicuris Gmbh & Co Kg Intravaginalt anvendelige indretninger omfattende antivirale forbindelser
FI3692039T3 (fi) 2017-10-05 2023-03-23 Innovative Molecules Gmbh Substituoitujen tiatsolien enantiomeerejä virusten vastaisina yhdisteinä
KR102535452B1 (ko) * 2018-07-06 2023-05-26 파에노 테라퓨틱스 씨오., 엘티디. 티아졸 화합물의 결정형 및 이의 응용
CA3113353A1 (en) * 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129717A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
JP2007314516A (ja) * 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd ２以上の置換基を有するベンゼン化合物を含有する医薬
AU2007257841A1 (en) * 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
DK2602258T3 (da) 2014-04-22
KR101768295B1 (ko) 2017-08-14
PH12015502801B1 (en) 2016-10-03
JO3734B1 (ar) 2021-01-31
MY185063A (en) 2021-04-30
US9340535B2 (en) 2016-05-17
KR20140066704A (ko) 2014-06-02
PH12015502801A1 (en) 2016-10-03
AU2015260762B2 (en) 2016-06-09
MX371088B (es) 2020-01-16
JP6353022B2 (ja) 2018-07-04
TWI532739B (zh) 2016-05-11
HRP20140351T1 (hr) 2014-07-04
PE20141148A1 (es) 2014-09-15
RU2669388C1 (ru) 2018-10-11
BR112014003245A2 (pt) 2017-03-01
PL2602258T3 (pl) 2014-08-29
EP2602258B8 (en) 2016-09-28
CA2791142C (en) 2017-08-01
KR20170055565A (ko) 2017-05-19
AU2015260762A1 (en) 2016-02-04
RU2014107430A (ru) 2015-11-10
CN105541829A (zh) 2016-05-04
EP2598501A1 (en) 2013-06-05
NZ621615A (en) 2016-04-29
ES2462492T3 (es) 2014-05-23
WO2013045479A1 (en) 2013-04-04
DK2598501T3 (da) 2014-04-22
KR20190104249A (ko) 2019-09-06
JP2014528948A (ja) 2014-10-30
RU2620604C2 (ru) 2017-05-29
ZA201408734B (en) 2016-08-31
ES2466221T8 (es) 2016-09-13
MY190878A (en) 2022-05-13
EP2602258A1 (en) 2013-06-12
IL234405A (en) 2015-04-30
HK1220978A1 (zh) 2017-05-19
UA115317C2 (uk) 2017-10-25
CN103842359B (zh) 2016-05-25
CA2791142A1 (en) 2013-03-26
NZ718867A (en) 2016-05-27
CN103842359A (zh) 2014-06-04
AU2012314536B2 (en) 2016-01-14
AR088043A1 (es) 2014-05-07
AR120291A2 (es) 2022-02-09
AU2012314536A1 (en) 2014-02-06
JP6161614B2 (ja) 2017-07-12
SG10201407430TA (en) 2014-12-30
TWI567070B (zh) 2017-01-21
TW201317234A (zh) 2013-05-01
CL2014000149A1 (es) 2014-09-05
PT2598501E (pt) 2014-06-25
EP2602258B1 (en) 2014-03-19
JO3037B1 (ar) 2016-09-05
MX338736B (es) 2016-04-29
EP2598501B1 (en) 2014-03-12
IL230152A (en) 2015-04-30
ZA201401773B (en) 2015-12-23
ES2466221T3 (es) 2014-06-09
US20140221433A1 (en) 2014-08-07
JP2017114859A (ja) 2017-06-29
PL2598501T3 (pl) 2014-08-29
UA119574C2 (uk) 2019-07-10
IN2014DN01993A (es) 2015-05-15
MX2014003389A (es) 2014-07-09
EP2573086A1 (en) 2013-03-27
TW201625603A (zh) 2016-07-16
KR20180088530A (ko) 2018-08-03

Similar Documents

Publication Publication Date Title
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
HK1217487A1 (zh) 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物
UA122520C2 (uk) Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
MX2014003623A (es) Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)-fenil]-n-metilacetamida con un intervalo de distribucion de tamaño de particula especifica y un intervalo de area superficial especifica para uso en formulaciones farmaceuticas.
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
UY34722A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil] etil}amino)-1-hidroxietil]-8- hidroxiquinolin-2(1h)-ona
CL2017002822A1 (es) Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol.
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
EA201591300A1 (ru) Формы меглуминовой соли 2-((1r,4r)-4-(4-(5-(бензоксазол-2-иламино)пиридин-2-ил)фенил)циклогексил)уксусной кислоты и их применение в качестве ингибиторов dgat1
CO6960546A2 (es) Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
PT2602258E (pt) Monohidrato de mesilato de n-[5-aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
BR112018013356A2 (pt) sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica
TR201902314T4 (tr) Azol benzen türevi ve bunun kristali.
BR112014003246A2 (pt) ácido n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]acetamida monometanossulfônico monohidratado cristalino e composição farmacêutica contendo partículas do mesmo
TH132151A (th) ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก
UA88738U (uk) 5-(гептилтіо)-3-(феноксиметил)-1н-1,2,4-тріазол, що виявляє антигіпоксичну активність
TH132151B (th) ((r)-(e)-2-(4-2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1 h-อินดาซอล-3- อิล)ไวนิล)-1 h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก